Michael Menzel
Overview
Explore the profile of Michael Menzel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
78
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ball M, Romanovsky E, Schnecko F, Kirchner M, Neumann O, Brandt R, et al.
J Mol Diagn
. 2024 Dec;
27(2):154-162.
PMID: 39674366
The adoption of comprehensive genomic profiling in oncology has rapidly increased the demand for standardized tumor sample processing in diagnostic laboratories. Automation of DNA and RNA library preparation workflows offers...
2.
Menzel M, Martis-Thiele M, Goldschmid H, Ott A, Romanovsky E, Siemanowski-Hrach J, et al.
Eur J Cancer
. 2024 Sep;
211:114306.
PMID: 39293347
Introduction: Whole Exome Sequencing (WES) has emerged as an efficient tool in clinical cancer diagnostics to broaden the scope from panel-based diagnostics to screening of all genes and enabling robust...
3.
Budczies J, Kazdal D, Menzel M, Beck S, Kluck K, Altburger C, et al.
Nat Rev Clin Oncol
. 2024 Aug;
21(10):725-742.
PMID: 39192001
Tumour mutational burden (TMB), defined as the total number of somatic non-synonymous mutations present within the cancer genome, varies across and within cancer types. A first wave of retrospective and...
4.
Ball M, Ourailidis I, Kluck K, Menzel M, Kirchner M, Allgauer M, et al.
J Mol Diagn
. 2024 Mar;
26(6):479-486.
PMID: 38522840
Targeted tumor only sequencing has become a standard practice in cancer diagnostics. This study aims to develop an approach for robust copy number variant calling in tumor samples using only...
5.
Pfarr N, von Schwarzenberg K, Zocholl D, Merkelbach-Bruse S, Siemanowski J, Mayr E, et al.
JCO Precis Oncol
. 2024 Mar;
8:e2300348.
PMID: 38513168
Purpose: Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown promising clinical results in the treatment of ovarian cancer. Analysis of biomarker subgroups consistently revealed higher benefits for patients with homologous recombination deficiency...
6.
Menzel M, Kirchner M, Kluck K, Ball M, Beck S, Allgauer M, et al.
J Pathol Clin Res
. 2024 Jan;
10(2):e354.
PMID: 38284983
This study analyzed whether extended molecular profiling can predict the development of epidermal growth factor receptor (EGFR) gene T790M mutation, which is the most frequent resistance alteration in non-small cell...
7.
Menzel M, Ossowski S, Kral S, Metzger P, Horak P, Marienfeld R, et al.
NPJ Precis Oncol
. 2023 Oct;
7(1):106.
PMID: 37864096
A growing number of druggable targets and national initiatives for precision oncology necessitate broad genomic profiling for many cancer patients. Whole exome sequencing (WES) offers unbiased analysis of the entire...
8.
Kazdal D, Menzel M, Budczies J, Stenzinger A
Dtsch Med Wochenschr
. 2023 Oct;
148(18):e111.
PMID: 37813377
No abstract available.
9.
Kazdal D, Menzel M, Budczies J, Stenzinger A
Dtsch Med Wochenschr
. 2023 Sep;
148(18):1157-1165.
PMID: 37657453
Molecular pathological diagnostics plays a central role in personalized oncology and requires multidisciplinary teamwork. It is just as relevant for the individual patient who is being treated with an approved...
10.
Menzel M, Endris V, Schwab C, Kluck K, Neumann O, Beck S, et al.
Transl Oncol
. 2023 Jun;
35:101706.
PMID: 37327584
Homologous recombination deficiency (HRD) is a predictive marker for response to poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian carcinoma. HRD scores have entered routine diagnostics, but the influence of algorithms,...